NASDAQ · FSTX
Healthcare · Biotechnology
$7.12
Up+$0.00 (+0.00%)
Updated Sep 16, 2026, 4:35 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
FSTX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning FSTX.
FSTX research
Company profile and research snapshot.
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 15, 2022 | HC Wainwright & Co. | Neutral | — |
| Jun 24, 2022 | SVB Leerink | Market Perform | — |
| May 11, 2022 | SVB Leerink | Outperform | — |
| Mar 17, 2022 | HC Wainwright & Co. | Buy | — |
| Aug 17, 2021 | SVB Leerink | Outperform | — |
No generated briefing is available yet.
Zacks Investment Research · Mar 9, 2023
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of -44.44% and 0.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswire Inc. · Jan 26, 2023
LONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK), and F-star Therapeutics, Inc. (“F-star”) (NASDAQ:FSTX), today issued the following statement regarding their pending transaction in response to a media report:
Benzinga · Dec 21, 2022
U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.93% to 33,156.76 while the NASDAQ rose 0.58% to 10,608.21. The S&P 500 also rose, gaining, 0.72% to 3,849.10. Read This Next: $7.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying Leading and Lagging Sectors Consumer discretionary shares jumped by 1.2% on Wednesday. Meanwhile, top gainers in the sector included NIKE, Inc. (NYSE: NKE), up 15%, and Six Flags Entertainment Corporation (NYSE: SIX), up 11%. In trading on Wednesday, communication services shares rose by just 0.2%. Top Headline The US current account deficit shrank by 9.1%, to $217.1 billion in the third quarter versus a revised $238.7 billion in the prior quarter and compared with market estimates of $222.0 billion. Equities Trading UP Sintx Technologies, Inc. (NASDAQ: SINT) shares shot up 51% to $11.25 after the company was awarded Phase I contract for $150,000 from the Missile Defense ...
GlobeNewswire Inc. · Dec 6, 2022
FS222 demonstrated early antitumor activity with one complete response and six disease stabilizations in patients with advanced solid tumors FS222 demonstrated early antitumor activity with one complete response and six disease stabilizations in patients with advanced solid tumors
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning FSTX.
No results
No recent SID articles mention FSTX.
